HNS is an innovative, minimally invasive therapy approved by both the U.S. Food and Drug Administration (FDA) and the Thai FDA. The procedure involves implanting a small device, known as Inspire®, under the skin in the chest. Connected to the hypoglossal nerve, the nerve that controls tongue movement, the device delivers gentle electrical stimulation during sleep. This stimulation moves the tongue forward, preventing airway collapse and allowing normal breathing. Surgery typically takes less than four hours, and most patients go home the next day.
Who is Eligible for HNS?
HNS is recommended for adults who:
- Are 18 years or older
- Have moderate to severe obstructive sleep apnea (OSA) AHI 15–100
- Struggle with or cannot tolerate CPAP therapy
- Have a body mass index (BMI) below 40 kg/m²
- Have appropriate airway anatomy and less than 25% central/mixed sleep apnea
- Do not have severe heart, lung, or neuromuscular disorders
Key Benefits of HNS
- No mask, hose, or bulky equipment needed
- Easy to activate with a small remote control
- Adjustable settings personalized to each patient
- Safe, with long-lasting results (battery life 7–11 years)
- Minimally invasive surgery with proven outcomes
- Supported by clinical research confirming safety and effectiveness
Why It Matters
Obstructive sleep apnea is more than a nighttime nuisance, it is a serious medical condition with long-term health consequences. By keeping the airway open naturally, HNS helps patients enjoy deeper, healthier sleep and improved quality of life.
At the Comprehensive Sleep Clinic at Bumrungrad International Hospital, a team of sleep specialists offers advanced diagnostics and tailored treatments, including hypoglossal nerve stimulation, to help patients breathe easier and sleep better.
Provide by the ENT Center at Bumrungrad International Hospital
